BioPharma Dive – AI / Data

Sarepta sees early success with RNAi drugs from Arrowhead

Published

2 weeks ago

on

Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version